SENORES PHARMACEUTICALS LIMITED (NSE: SENORES, BSE: 544319) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹5,403 Cr, it ranks #813 by market cap among the 6,197 Indian listed companies on FinBizNet, and #16 of 63 in Pharmaceuticals. At ₹1,171.10 (as of 16 Nov 2026), the share price is 26.8% below its 52-week high of ₹1,599.00 and 65.9% above its 52-week low of ₹706.00. The share price is up 42.7% over one year and down 21.2% over three months.
| Current Price | ₹1,171.10 |
|---|---|
| Market Cap | ₹5,403 Cr |
| NSE Symbol | SENORES |
| BSE Code | 544319 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 48.6 |
| Return on Equity | 13.68% |
| Return on Assets | 6.05% |
| 52-Week Range | ₹706.00 – ₹1,599.00 |
| 1-Year Price Change | +42.7% |
| 3-Month Price Change | -21.2% |
| Beta (1Y) | 0.27 |
| Headquarters | Ahmedabad, Gujarat |
| Website | senorespharma.com |
| Revenue | ₹192 Cr |
|---|---|
| Net Profit | ₹37 Cr |
| Net Margin | 19.0% |
| EPS (Basic) | ₹8.85 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
SENORES PHARMACEUTICALS LIMITED reported revenue of ₹192 Cr in Q2 FY27, up 18.9% from ₹162 Cr in Q2 FY26 and up 6.7% from ₹180 Cr in Q1 FY27. It posted a net profit of ₹37 Cr for the quarter, against a net profit of ₹30 Cr in Q2 FY26 (up 21.5%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹114 Cr (Q4 FY25) to ₹192 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹192 Cr | ₹37 Cr | 19.0% |
| Q1 FY27 | ₹180 Cr | ₹30 Cr | 16.9% |
| Q4 FY26 | ₹175 Cr | ₹37 Cr | 20.9% |
| Q3 FY26 | ₹175 Cr | ₹34 Cr | 19.2% |
| Q2 FY26 | ₹162 Cr | ₹30 Cr | 18.6% |
| Q1 FY26 | ₹138 Cr | ₹21 Cr | 15.3% |
| Q4 FY25 | ₹114 Cr | ₹18 Cr | 15.7% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 45.82% of SENORES PHARMACEUTICALS LIMITED's shares as of Sept 2026, against 45.80% in Sept 2025 (+0.02 percentage points). Delivery averaged 41.8% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
1. Pharmaceuticals-This segment engages in developing and manufacturing a range of pharmaceutical products across various therapeutic areas and dosage forms. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| SENORES PHARMACEUTICALS LIMITED | ₹5,403 Cr | 48.6 | 13.68% | ₹192 Cr | +42.7% |
Listed by market capitalisation. Ratios are shown for context only.
SENORES PHARMACEUTICALS LIMITED is trading at ₹1,171.10, with a market capitalisation of ₹5,403 Cr.
SENORES PHARMACEUTICALS LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
SENORES PHARMACEUTICALS LIMITED has a P/E of 48.6 and a return on equity of 13.68%.
SENORES PHARMACEUTICALS LIMITED is listed on the NSE under the symbol SENORES and on the BSE under the scrip code 544319.
SENORES PHARMACEUTICALS LIMITED's share price is up 42.7% over one year and down 21.2% over three months. Its 52-week range is ₹706.00 to ₹1,599.00.
In Q2 FY27, SENORES PHARMACEUTICALS LIMITED reported revenue of ₹192 Cr and net profit of ₹37 Cr, with basic EPS of ₹8.85 (consolidated, parsed from the company's exchange filing).
SENORES PHARMACEUTICALS LIMITED reported revenue of ₹192 Cr in Q2 FY27, up 18.9% from ₹162 Cr in Q2 FY26 and up 6.7% from ₹180 Cr in Q1 FY27.
Promoters held 45.82% of SENORES PHARMACEUTICALS LIMITED's shares as of Sept 2026, against 45.80% in Sept 2025 (+0.02 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.